Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04146363 · ClinicalTrials.gov registry record · Phase 3
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)
A Phase 3 study of Atopic Dermatitis, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 424
- Enrollment target
- 20
- Study locations
NCT04146363 is a Phase 3 study of Atopic Dermatitis that has completed, run by Eli Lilly and Company. The registered enrollment target is 424 participants, below the 607-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (30% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT04146363, a Phase 3 study of Atopic Dermatitis, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 424 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, double-blind, placebo-controlled, parallel-group study which is 52 weeks in duration. The study is designed to confirm the safety and efficacy of lebrikizumab as monotherapy for treatment of moderate-to-severe atopic dermatitis utilizing a 16-week induction treatment period and a 36-week long-term maintenance treatment period.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Lebrikizumab
Study Locations (20)
California
- Wallace Medical Group, Inc. - Beverly Hills
- California Dermatology & Clinical Research Institute - Encinitas
- Belle Aimee Skincare Clinic - Fountain Valley
- Dermatology Research Associates - Los Angeles
- ACRC Studies - San Diego
Florida
- St. Francis Medical Institute - Clearwater
- Community Research Foundation Inc - Miami
- ForCare Clinical Research - Tampa
Michigan
- Henry Ford Hospital - Detroit
- St Joseph Dermatology and Vein Clinic - Saint Joseph
Arkansas
- Johnson Dermatology - Fort Smith
Connecticut
- Central Connecticut Dermatology - Cromwell
Georgia
- IACT Health - VHC - Columbus
Indiana
- The Indiana Clinical Trials Center - Plainfield
Kentucky
- Skin Sciences, PLLC - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 424 participants |
| Start Date | 2019-09-24 |
| Est. Completion | 2022-05-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04146363
The ClinicalTrials.gov registry entry for NCT04146363 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 424 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 607-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (30% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04146363 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT04146363 about?
NCT04146363 is a clinical study titled "Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)". This is a randomized, double-blind, placebo-controlled, parallel-group study which is 52 weeks in duration. The study is designed to confirm the safety and efficacy of lebrikizumab as monotherapy for treatment of moderate-to-severe atopic dermatitis utilizing a 16-week induction treatment period and...
What is the current status of trial NCT04146363?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 424 participants. The study started on 2019-09-24. Estimated completion is 2022-05-03.
What conditions does trial NCT04146363 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT04146363?
The interventions under investigation include: Placebo (OTHER), Lebrikizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04146363?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04146363 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
RECRUITING · Phase 3
-
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
RECRUITING · Phase 3
-
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
RECRUITING · Phase 3
-
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.